Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.

Adriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, Chiara Landolfo, Els Van Nieuwenhuysen, Karin Leunen, Patrick Neven, Frédéric Amant, Sven Mahner, Elena Ioana Braicu, Robert Zeilinger, An Coosemans, Dirk Timmerman, Diether Lambrechts, Ignace Vergote

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 2018;23(9):2223-2231

PMID: 27852697

Abstract

Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy-number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass. We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing. Patterns of chromosomal instability were detectable in cell-free DNA using 44 healthy individuals as a reference. Profiles were representative of those observed in matching tumor tissue and contained CNAs enriched in two large datasets of high-grade serous ovarian cancer (HGSOC). Quantitative measures of chromosomal instability, referred to as genome-wide -scores, were significantly higher in patients with ovarian carcinoma than in healthy individuals or patients with benign disease. Cell-free DNA testing improved malignancy detection (AUC 0.89) over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC 0.81). AUC values of cell-free DNA testing even further increased for HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a theoretical threshold required for ovarian cancer screening, sensitivity of cell-free DNA testing was 2- to 5-fold higher compared with CA-125 and RMI testing. This is the first study evaluating the potential of cell-free DNA for the diagnosis of primary ovarian cancer using chromosomal instability as a read-out. We present a promising method to increase specificity of presurgical prediction of malignancy in patients with adnexal masses. .

©2016 American Association for Cancer Research.

Address: Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.; Division of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.; Vesalius Research Center, VIB, Leuven, Belgium.; Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium.; Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.; Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.; Division of Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.; Department of Gynecology and Gynecologic Oncology, Hamburg-Eppendorf University Medical Center, University Cancer Center Hamburg-Eppendorf (UCCH), Hamburg, Germany.; Department of Gynecology and Obstetrics, University of Munich - LMU, Munich, Germany.; Department of Gynecology, Campus Virchow-Klinikum, Charité University Hospital, European Competence Center for Ovarian Cancer, Berlin, Germany.; Department of Obstetrics and Gynecology, Molecular Oncology Group, Comprehensive Cancer Center, Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.; Vesalius Research Center, VIB, Leuven, Belgium. [email protected].; Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.